Skip to main content

Volume 14 Supplement 1

Canadian Anxiety Disorders Guidelines Initiative: Clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders


Edited by Mark Powers

Unrestricted educational grants for the development of these guidelines and publication of this supplement were provided by Astra Zeneca Canada, Eli-Lilly Canada, Janssen Inc, Lundbeck Canada, Pfizer Canada, Purdue Canada, Servier Canada Inc, Shire Canada and Valeant Canada. None of the members received payment for participating in the development of these guidelines. The article has undergone the journal's standard peer review process for supplements. The Supplement Editor is funded by a grant from the National Institute on Drug Abuse K01 DA035930 and declares that he has no other competing interests.

  1. Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.

    Authors: Martin A Katzman, Pierre Bleau, Pierre Blier, Pratap Chokka, Kevin Kjernisted and Michael Van Ameringen
    Citation: BMC Psychiatry 2014 14(Suppl 1):S1

Annual Journal Metrics

  • 2022 Citation Impact
    4.4 - 2-year Impact Factor
    4.9 - 5-year Impact Factor
    1.535 - SNIP (Source Normalized Impact per Paper)
    1.291 - SJR (SCImago Journal Rank)

    2023 Speed
    31 days submission to first editorial decision for all manuscripts (Median)
    146 days submission to accept (Median)

    2023 Usage 
    7,538 Altmetric mentions 

Peer-review Terminology

The following summary describes the peer review process for this journal:

Identity transparency: Single anonymized

Reviewer interacts with: Editor

Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

More information is available here

Sign up for article alerts and news from this journal